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The effects of components of aqueous licorice root extract (LE) on the pharmacokinetics of glycyrrhizin (G) and glycyrrhetic acid (GA) were
investigated in rats and humans. The aim of this work was to define the role of pharmacokinetics in G toxicity. In the procedure, G and GA were
detected in biological fluids by means of recently improved HPLC methods. Significantly lower G and GA plasma levels were found in rats and
humans treated with LE compared to the levels obtained with those in which G alone was administered. The pharmacokinetic curves showed
significant differences in the areas under the plasma-time curve (AUC), Cmax, and Tmax parameters. The data obtained from urine samples are in
agreement with the above results and confirm a reduced bioavailability of G present in LE compared to pure G. This should be attributed to the
interaction during intestinal absorption between the G constituent and the several components in LE. The modified bioavailability could explain the
various clinical adverse effects resulting from the chronic oral administration of G alone as opposed to LE. -Environ Health Perspect 102(Suppl
9):65-68(1994)
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Introduction
Aqueous liquorice root extract (LE) is pre-
pared from Glycyrrhiza glabra L. varieties
and is a black mass containing several con-
stituents and having a characteristic sweet
taste. In particular, LE contains gly-
cyrrhizin (G) (or glycyrrhizinic acid), a
saponinlike glycoside that is 50 times
sweeter than sugar. Upon hydrolysis, the
glycoside loses its sweet taste and is con-
verted to aglycone glycyrrhetic acid, a pen-
tacyclic triterpene derivative of the
P-amyrin type (Figure 1), plus two mole-
cules of glucuronic acid. Other compo-
nents of LE include flavonoid glycosides
(liquiritin, isoliquiritin, liquiritoside,
isoliquiritoside, rhamnoliquiritin, and
rhamnoisoliquiritin), coumarin derivatives
(herniarin and umbelliferone), asparagine,
22,23-dihydrostigmasterol, glucose, man-
nitol and about 20% starch (1).
LE is used for some therapeutic pur-
poses. It was the Dutch physician Revers
who discovered that LE contains a sub-
stance with spasmolytic power and with a
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Figure 1. Chemical structure of glycyrrhizin (I) and gly-
cyrrhetic acid (II).
beneficial influence on the healing process
of gastric ulcers (2). In addition, gly-
cyrrhetic acid has also been shown to pos-
sess antiinflammatory action which has led
to its use in ointments for dermatological
disorders (3). Other possible therapeutic
properties of G have been studied
such as antiallergic (4), antiarthritic (5),
anticholinergic (6), antiestrogenic (7),
antihepatotoxic (8) antileukaemogenic (9),
and antiviral (10). Furthermore, G is used
as a sweetening agent in many food and
luxury products such as licorice, chocolates,
beer, liquors and chewing gum. However,
serious side effects related to glycyrrhizin
ingestion, including headaches, edema,
body weight increase, and disturbances in
body-electrolyte balance were observed
either after daily high LE personal con-
sumption or in clinical use (11).
In the present work, which is part ofan
extensive study on the behavior and toxic-
ity ofG, an attempt was made to compare
the bioavailabiliy of G after oral adminis-
tration of G alone or G in LE in rats and
humans to evaluate the interactive effects
between G and several LE components
during intestinal absorption.
Materials and Methods
Chemicals
Glycyrrhizin (glycyrrhizic acid ammonium
salt), glycyrrhetic acid, and propyl-4-
hydroxybenzoate or Paraben (PPB) were
purchased from Fluka (Buchs, Switzer-
land). Aqueous licorice root extract with a
G content of 7.64% was supplied by
SAILA S.p.A. (Silvi Marina (TE), Italy).
Methanol, ethanol, acetonitrile, acetic acid,
and all other reagents were obtained from
Merck (Darmstadt Germany). Analytical
grade ultrapure water from Millipore milli-
Q (Millipore) was used.
The stock solutions of G and GA were
prepared by dissolving 50 mg of G or GA
in 50 ml ofethanol. The stock solution of
PPB (2 x 10-2M) was obtained by dissolv-
ing 72 mg of PPB in 20 ml of methanol.
The standard solutions were all prepared
by diluting the stock solution with
methanol (11).
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Apparatus and Chromatographic
Conditions
The HPLC system consisted of a Varian
9001 chromatographic pump and Water
(Millipore) 481 detector. Separation was
achieved on a reverse-phase column (250
mm x 4 mm I.I., 5 pm, RP-18, Merck) fit-
ted with a column inlet filter.
The mobile phase consisted of acetoni-
trile-water-acetic acid (36:64:0.5, v/v) for
G and methanol-water-acetic acid (83:17:
0.5, v/v) for GA. The mobile phase was
used at a flow rate of 1.0 ml/min for G and
of0.85 ml/min for GA. These experimental
conditions are based on those ofZhang et
al. (12) with some modifications. The col-
umn was maintained at room temperature
and the chromatograms were monitored at a
wavelength of 251 nm throughout the
experiments. Data processing was handled
by aWaters (Millipore) 745 integrator.
Experimenal Procedure in Rats
Sprague-Dawley rats (300 ± 30 g, bw) were
divided into groups (four male and four
female) with fasting for about 16 hr prior
to experiments but with water allowed ad
libitum. G and LE in water solution were
administered by gavage at proportional
doses with G ranging from 40 to 480
mg/kg, body weight. At 1, 2, 4, 6, 8, 10,
12, 16, 24, 36 hr after the treatments, the
animals were anesthetized with ethyl ure-
thane (15% solution, ip). Blood was col-
lected in EDTA tubes by cardiac puncture
and centrifuged at 3000 rpm for 30 min.
Subsequently, the plasma was separated
and stored at -200C until analysis.
The urinary excretion ofG and GA was
studied over 12-, 24- and 36-hr intervals
after oral administraton of the maximum
dosage (G: 480 mg/kg bw; LE: 6276
mg/kg bw). Each treated rat was housed
separately in a clean metabolic cage for
urine collection with only drinking water
available. The exact volume of urine col-
lected from each animal was measured and
each urine sample centrifuged at 1500 rpm
for 10 min and stored in freezer (at
-200C) until analysis.
Experimental Procedure in Humans
Eight healthy volunteers ofboth sexes were
used in different combinations to detect G
and GA concentration levels in their plasma
samples. G and LE in water solution were
orally administered in doses ofeither 800
or 1600 mg as G. Venous blood samples
were collected in EDTA tubes at 1-, 2-, 4-,
6-, 8-, 12-, 24- and 36-hr intervals after
treatment, centrifuged and the plasma sepa-
rated and stored at -200C until analysis.
The urine of each volunteer was col-
lected over 36 hr after G or LE administra-
tion at 0-, 4-, 8-, 12-, 24- and 36-hr
intervals.
Analytical Procedure
Samples of 1 ml for plasma and urine were
used for G and GA determination. After
vigorous shaking with 5 ml of methanol
for 20 min, the samples were centrifuged
for 30 min at 2000 rpm (13). For the G
analysis, to the methanol used was added
an internal standard PPB (2.5 x 10-7
moles/l). Then, the supernatant liquid was
vacuum dried. The residue was dissolved in
400 p1 ofmethanol and filtered through a
Millipore membrane filter (0.45 pm). A
50-pl aliquot of the solution was injected
for each time course into the HPLC.
The G concentration was calculated by
the peak area method using an internal stan-
dard (PPB), and GA by the peak area me-
thod with external standard because there is
no appropriate internal standard for GA.
Results and Discussion
Animal Study
In the rat, plasma levels of G after oral
administration ofG at doses of40, 80, and
120 mg/kg bw or at theproportional dosages
of LE (523, 1046, 1569 mg/kg/bw) were
lower than the limit ofsensivity of HPLC
(0.2 pg/ml). However, as can be seen from
Figure 2a, it was possible to determine G
concentration in the plasma of the rats
treated with 160 mg/kg/bw, ofG while, on
the contrary, G concentrations were below
or near to the limit ofsensitivity (0.2 pg/ml)
in the samples treated with a corresponding
LE dose, that contains the same amount of
G as in the pure compound, of 2092
mg/kg/bw. To detect a more appreciable
amount ofthe test compound in the plasma,
both for G and LE, it was necessary to
administer higher quantities ofboth G (480
mg/kg/bw) and LE (6276 mg/kg/bw). This
is supported by earlier studies in the available
literature (12,14,15). From these higher
doses, Figure 2b shows that the plasma
levels ofG in rats treated with LE were con-
siderably and significantly lower for each
sample-time than those obtained after ad-
ministration ofG. This supports findings at
the lower dose, Figure 2aalthough results for
LE were largely undetectable. To define the
different pharmacokinetics ofG, Table 1
gives some parameters ofthe above prepara-
tion. In fact, the area under the plasma time-
curve (AUC) values for G treatment were
more than two times higher than the AUC
LE. On the other hand, the Cmax of G is
C, 1.
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Figure 2. Plasma levels in rat of glycyrrhizin (G) after
oral aministration of glycyrrhizin (G) or aqueous licorice
root extract (LE). Each point represents the mean value
from six to eight animals. The statistical analysis was
carried out by Student's t-test. ** Significant level at p<
0.01; * Significant level at p< 0.05.
increased 3-fold in comparison with the
C,a.obtained from animals treated with LE.
The time required for a maximum concen-
tration (Tma.d ofG was 12 hr after adminis-
tration ofLE, while G reaches Tmacx at 10 hr
after administration of G alone. Similar
results are reported in the literature from
experiments in rat (14) and rabbit (12).
In urine experiments the results ob-
tained for G and GA contents at 12-, 24-,
and 36-hr intervals after oral treatment are
reported in Figures 3a and 3b respectively.
Ifcompared with administered dosage, the
G and GA excreted is very low reflecting
the low plasma concentration. However, at
all these periods oftime it is clearly evident
that both G and GA excretions are signifi-
cantly higher in animals treated with G
alone than in those treated with LE. Thus,
the above data and preliminary results
Table 1. Pharmacokinetic parameters of g in plasma
after oral administration of aqueous solution of LE or G
a in rats.
AUC36h, Cmax,
Compounds pgxhr/ml pg/ml Tmax, hr
Glycyrrhizin 53.4 ± 6.3 4.8 ± 0.5 10
(480 mg/kg)
Licorice 20.9 ± 3.2 1.5 ± 0.2 12
(6276 mg/kg)
aData are the mean
± SE of six to eight rats; bp<0.01.
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Figure 3. Urinary excretion in rat of glycyrrhizin (G) (a)
or glycyrrhetic acid (GA) (b) after oral administration of
glycyrrhizin (G) or aqueous licorice root extract (LE).
Each bar represents the mean ± SD of the percentage
of G or GA excreted at each interval period and cumu-
latively (0-36 hr) by six to eight animals.The statistical
analysis was carried out by the Student's t-test. **
Significant level at p<0.01;* Significant at p< 0.05.
from a bile excretion study (0-16 hr) in
progress confirm the plasma level values
which indicate that when G is a compo-
nent of LE, G has a significantly reduced
intestinal absorption rate than if it is
administered alone.
HumanStudy
In experiments with human volunteers, it
was not possible to detect G content in
plasma samples at all considered interval
times within 36 hr after single G and Ll
oral administration (G, 0.8 g, LE, 10.5 g).
Only from analysis of one volunteer, who
had been given double quantities ofG (1.6
g), did we find, and then only during some
ofthe test periods, detectable plasma levels
of G; however, a week later and in the
same volunteer, after LE administration
(21 g) no detectable G level was found as
shown in Figure 4.
After this finding, a set ofexperiments
were performed in another volunteer group
to establish their plasma levels ofGA, which
is the principal G metabolite derived from
hydrolysis ofthe sugar chain. For example,
Figure 5 shows the plasma pharmacokinetics
of GA in two individual volunteers, one
male (Figure 5a) and one female (Figure
5b), after a single oral administration of G
alone (1.6 g) and then an LE dosage 1 week
later (21 g). The G plasma levels in both
cases are lower at all intervals (0-36 hr) in
do, however, confirm the results obtained
AG (1 .6g) on the rat experiments. In comparing G and > LE (21 g) LE treatments, GA excretion in humans
limit of sensitivity showed no differences, and GAwas detected
at essentially similar quantities in both treat-
ments only in urine excretion between 12
and 24 hr (Figure 61). Thus, the human
....... results are in total agreement with those
. I *T -;4 obtained in the animal study. Therefore, it is
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Figure 4. Plasma levels of glycyrrhizin (G) after oral
administration of glycyrrhizin (G) or aqueous licorice
root extract (LE) in one male volunteer.
LE administration when compared with sin-
gle component (G) administration.
However, the spread between male and
female results, particularly up to 12 hr, is
considerable in thevolunteers.
Similar to the results obtained in rat
experiments, the amounts of G or GA
excreted were also very low in urine col-
lected from the two above-mentioned vol-
unteers at 4, 8, 12, 24, and 36 hr after either
G or LE administration at the highest
dosage. However, at all the time intervals
considered, Figure 6a shows that the G
excretion averaged a lower value with LE
than with G administration. The results
having been based on only two volunteers
are valuable only as a trend indication, but
2.5-
2-
AG (1.6 g)
0 O~~~~~LE (21 g) 1.5
0 1-
wnen it is a component or LEas opposec to
administration alone.
Conclusions
The excellent sensitivity of the HPLC
procedure, modified especially for this
experiment (16), assures the accurate
reproducible results obtained throughout
this study. The findings both in animal and
human models clearly confirm a lower
bioavailability of G when orally consumed
as a component of LE. A reduced rate of
intestinal absorption explains the lower
plasma and urine levels ofG during the 36
hr observation period after LE administra-
tion as compared with that obtained after
G administration alone at a corresponding
quantity ratio.
One can, therefore, assume that there is
positive interaction between G and one or
more of the several substances that are
components of aqueous licorice root
extract (LE).
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Figure 5. Plasma levels of glycyrrhetic acid (GA) after
oral administration of glycyrrhizin (G) or aqueous
licorice root extract (LE) in male (a) and female (b) vol-
unteers.
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Figure 6. Urinary excretion in humans of glycyrrhizin (G)
(a) or glycyrrhetic acid (GA) (b) after oral administration
of glycyrrhizin (G) or aqueous licorice root extract (LE).
Each bar represents the mean of the percentage of G
and GA excreted, respectively, at each interval period
bythe same two volunteers of Figures 4,5.
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It is well known that several compo-
nents in food constituents can interact with
drugs and produce modified intestinal
absorption (17). In general, an altered
bioavailability of a drug can result in
reduced therapeutic action or can increase
undesirable side effects (17).
The clinical implications of this phe-
nomenon can prove highly important
when the drug is consumed orally and for
long periods of time. In the present situa-
tion, the interaction between G and the LE
components represents an advantage since
the lower intestinal absorption ofG means
a reduced incidence ofside effects. In fact,
a recently completed parallel clinical study
on the chronic oral consumption ofaque-
ous liquorice root extract (LE) in high
doses for 4 week confirms our findings
(18,19).
In conclusion, it is important to restate
that this study clearly indicates that the
continuous consumption of licorice root
extract in daily use as food or for therapeu-
tic purposes is safer than the use of gly-
cyrrhizin alone or when the latter is added
to man-made products (sweets, chewing
gum, drinks, drugs, etc.). From the results
of this paper, it is well demonstrated that
LE reduces the toxicity ofG probably due
to component interaction before and/or
during intestinal absorption, providing an
increasing measure ofsafety.
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